Category: Medtech
Ivenix Appoints John Douglass as Board of Directors Executive Chair
Cytek Biosciences Ships 100th Advanced Flow Cytometry System
Company Ramping up Production to Meet Increasing Global Demand
FREMONT, Calif., Dec. 20, 2018 (GLOBE NEWSWIRE) — Cytek Biosciences Inc., the preeminent provider of innovative flow cytometry solutions, has marked a significant milestone: the company has shipped 100 of its advanced flow cytometry systems. First introduced in June of last year, Cytek’s systems are rapidly gaining traction with scientists around the globe – giving them the ability to obtain deeper biological insights from a single sample and accelerate their fields of research.
A technique used to detect and measure the physical and chemical characteristics of a population of cells or particles, flow cytometry has become an invaluable tool in research and clinical studies with various biomedical and therapeutic applications such as investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients. While the benefits offered by flow cytometry are well known throughout the scientific community, adoption has lagged due its cost-prohibitive, workflow-intensive nature.
“At Cytek, we are focused on far more than just selling units – we are fueling a movement,” noted Dr. Wenbin Jiang, CEO of Cytek Biosciences. “We’re on a mission to make the advanced instrumentation that was once available to very few scientists accessible to more researchers, and this latest achievement is a strong indicator that our mission is resonating strongly with the scientific community.”
Cytek’s systems provide ease of use, an unusually high performance-to-price ratio, experimental design flexibility and high-quality data. Additionally, its three laser flow cytometer makes more than 24 colors possible. The company is fast becoming the go-to flow cytometry source for scientists in immunology, immuno-oncology, leukemia and lymphoma labs, cancer/stem cell research, and extra-cellular vesicle research. In fact, robust global sales have led Cytek to ramp up manufacturing and expand its operations team in order to keep up with demand.
“The sale of our one hundredth system in less than 18 months is an indication that our technology is hitting the sweet spot for price and performance,” continued Jiang. “We plan to keep this momentum going by continuing to extend and accelerate our reach and capabilities.”
Cytek Biosciences Continues Momentum by Strengthening Executive Team, Adding Board Members
Company’s Advanced Flow Cytometry Systems Being Embraced by Scientists, Clinicians Around the World
FREMONT, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) — Cytek Biosciences Inc., the preeminent provider of innovative flow cytometry solutions, today announced that Steve Ziganti and Patrik S. Jeanmonod have joined the company’s leadership team in the roles of vice president of worldwide sales and chief financial officer, respectively. Additionally, Jack Ball and Dr. Allen Poirson have been added to Cytek’s board of directors.
From pharmaceutical and biotech companies to contract research organizations, the scientific community is embracing Cytek’s Aurora and Northern Lights flow cytometry systems with open arms – and this success is driving the expansion of the company. Cytek is focused on making the advanced instrumentation that was once available to very few scientists accessible to more researchers. With Cytek’s systems, more labs will have the ability to obtain deeper biological insights from a single sample – and accelerate their fields of research.
Cytek Biosciences Debuts Advanced Flow Cytometry System that Breaks the Cost Barrier
FREMONT, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) — The door to discovery has been opened, and the traditional flow cytometry market is set to see a paradigm shift. With its new Northern Lights series of advanced flow cytometry systems, Cytek Biosciences Inc. is making three lasers and more than 24 colors possible at a price point typically attached to systems with far fewer capabilities. Cytek™ Northern Lights is the latest in a series of technological advances that furthers Cytek’s mission to make full-spectrum flow cytometry accessible to a larger number of scientists. And they aren’t done yet.
There is a pressing need for increased access to intuitive, high-capability flow cytometers and the deep biological insights that they bring. In fact, rapidly growing areas of research – such as CAR-T cell therapy and immuno-oncology – are driving the flow cytometry analyzer market, which is expected to grow to more than $1 billion dollars by 2020.
Incorporating the same spectral technology that Cytek has become known for in its flagship series, Cytek™ Aurora, Northern Lights offers a value-added package with capabilities that go beyond flow cytometry systems with a much higher price tag. For example, with Northern Lights, scientists can now extract the same amount of information from one sample that would take three or four tubes using a conventional cytometer with a similar price. With this extraordinary price-performance ratio and low total cost of ownership, Northern Lights sits in a sweet spot for scientists that have budgeted for a one to three laser system – but desire the ability to run panels that range from lower to higher complexity.
b-ONE Ortho Receives U.S. FDA 510(k) Clearance for Total Hip System
CEDAR KNOLLS, N.J.–(BUSINESS WIRE)–b-ONE Ortho Corp., an emerging orthopedic technology company dedicated to the development of innovative healthcare solutions, today announced it has received 510(k) clearance for its first device, the b-ONETM Total Hip System, from the U.S. Food and Drug Administration (FDA).
The b-ONETM Total Hip System is a cementless total hip system with advanced coating technology and intuitive instrumentation, designed to optimize patient fit in the modern patient demographic. The system comprises the JuvenoTMFemoral Hip, a bone-conserving femoral prosthesis, and the b-ONE Primary Acetabular System, which are compatible with b-ONETM 12/14 Taper Femoral Heads.
Ivenix to Showcase Patient-Centered Infusion System at NTI 2018
BOSTON — Ivenix, a medical technology company with the vision of eliminating infusion-related patient harm, today announced it will showcase its innovative infusion system and offer continuing education sessions at the 2018 National Teaching Institute (NTI) and Critical Care Exposition, which takes place from May 21 to May 24 in Boston.
Infusion-related errors are responsible for 54 percent of the approximately 1.5 million adverse drug events reported to the U.S. Food and Drug Administration (FDA) annually. Sixty-one percent of those adverse events are reported to be serious or life-threatening. The Ivenix Infusion System includes a large volume infusion pump with intuitive infusion delivery designed to inform clinical workflow, enhance patient experience and help improve patient safety.
Ivenix will host the following 30-minute continuing education sessions during the NTI ExpoEd at Booth 1905.
F-Prime Capital Partners Announces Parker Moss as New Entrepreneur-in-Residence
CAMBRIDGE, Mass.–(BUSINESS WIRE)–F-Prime Capital Partners, a global venture capital firm focused on investments in life sciences, healthcare and technology, today announced that Parker Moss has joined the firm as entrepreneur-in-residence. Parker will be based in London and will focus on health technology investments and company-creation activities.
“We are excited to welcome Parker to the firm – he is an important addition to the F-Prime team,” said Stephen Knight, managing partner of F-Prime Capital Partners. “Parker’s experience as a senior executive in the healthcare and telecom industries, and his strong conviction and determination for transforming healthcare delivery, will be invaluable as we push further into building and investing in health technology companies. His hands-on experience on the frontline of both the hospital and the community sectors of the NHS has given him an acute sense of the barriers and opportunities for disruptive innovation in medical research, on the wards and in patients’ homes, and we look forward to working with Parker to bring some of these exciting opportunities to market.”
Science 2 Startup Symposium Convened Over 230 Academic Researchers, Venture Capitalists, Entrepreneurs, and Pharmaceutical Executives, Creating Connections that can Advance Scientific Innovation and Entrepreneurship
Symposium Exposed Academics to Investors and Executives Who Could Help Guide Them to the Next Level
CAMBRIDGE, Mass., May 04, 2018 (GLOBE NEWSWIRE) — Science 2 Startup, an invitation-only event, convened over 230 members of the biotech ecosystem at the Broad Institute of MIT and Harvard last week. Approximately half of the attendees were venture capital and other investors, a quarter were biopharma executives and entrepreneurs, and a quarter were the academic investigators and their technology transfer professionals from top research institutions.
Science 2 Startup was created and presented by Boston-area venture capital firms Atlas Venture, F-Prime Capital Partners, and SV Health Investors. The scientists and other academic representatives came from three countries and all over the US.
The agenda underscored the intensity of the biotech ecosystem and the relevance and interdependence of all of its players: scientists, entrepreneurs, the pharmaceutical industry, and funding sources.
Cytek Biosciences Spotlights the Cytek Aurora Flow Cytometry System at CYTO 2018
PRAGUE, Czech Republic (GLOBE NEWSWIRE) — This week at the industry’s premier flow cytometry conference, CYTO 2018, Cytek Biosciences Inc. will be on the show floor highlighting its CytekTM Aurora flow cytometry system with enhanced features. This unique platform has been embraced by researchers around the world since making its debut at CYTO 2017, and the deployments so far have been validating the application flexibility of the Cytek Aurora. From extra-cellular vesicles to highly multiparametric applications beyond what were initially envisioned and more, the breadth of applications being performed on the Cytek Aurora continues to grow.
“At this time last year, we introduced the scientific community to an all-new full spectrum flow cytometer that enables new discoveries and deeper biological insights at an affordable cost,” noted Dr. Wenbin Jiang, CEO of Cytek Biosciences. “Now, Cytek Aurora has been sold into four continents and is at work all over the globe. CYTO 2018 is the perfect place for us to showcase how we have expanded Cytek Aurora’s features and application abilities over the past year and set the stage for future innovations to come.”